Biomedicines

OCT 23, 2026 · JOURNAL ARTICLE

Targeted Therapies for EGFR Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer

Biomedicines

Lung cancer remains the leading cause of cancer-related death worldwide. Epidermal growth factor receptor (EGFR) mutations are among the most common oncogenic drivers in non-small

OCT 22, 2026 · JOURNAL ARTICLE

Tight Glycemic Control in a Vulnerable Population: Diabetes Treatment Patterns in Patients with Hematologic Malignancies

Biomedicines

Background: Diabetes management in patients with hematologic malignancies is challenging because of advanced age, multimorbidity, and cancer-related therapies. However, real-world

OCT 22, 2026 · JOURNAL ARTICLE

Immune-Mediated Endothelial Injury in Cardiometabolic–Cardiovascular Disease

Biomedicines

Cardiometabolic disease, encompassing hypertension, type 2 diabetes, obesity, and dyslipidemia, is the predominant driver of cardiovascular disease (CVD) morbidity and mortality wo

OCT 22, 2026 · JOURNAL ARTICLE

TAK1 Is Associated with Lipid-Induced Macrophage Polarization in Obesity Cardiomyopathy: Evidence from Network Pharmacology and Experimental Validation

Biomedicines

Objective: To investigate whether TAK1 regulates lipid-induced macrophage polarization and contributes to inflammatory progression in obesity cardiomyopathy (OCM). Background: OCM

OCT 19, 2026 · JOURNAL ARTICLE

Antibody Targeting Soluble NKG2D Ligand MIC Enhances Adoptive T-Cell Therapy in an NK Cell-Dependent Mechanism

Biomedicines

Background/Objectives: Antigen-specific adoptive CD8+ T-cell therapy has demonstrated promising clinical activity in selected cancers; however, its broader efficacy against solid t

OCT 16, 2026 · JOURNAL ARTICLE

Metabolically Unhealthy Obesity: Novel Subtypes Defined by Integrated Metabolomics and Hematology

Biomedicines

Objectives: The aim was to identify metabolic subtypes within metabolically unhealthy obesity (MUO) using integrated metabolomics and hematology data and evaluate their differentia

OCT 14, 2026 · JOURNAL ARTICLE

Advancing the Translational Pipeline: From In Vivo and In Vitro 2D Models to Next-Generation Cell Culture Models for Amyotrophic Lateral Sclerosis Modelling and Drug Discovery

Biomedicines

Background: Amyotrophic lateral sclerosis (ALS) is still a global health challenge, as there is no effective treatment due to the inadequacy of conventional experimental platforms

OCT 14, 2026 · JOURNAL ARTICLE

Ingramon-Depot Therapy in db/db Mice: The Impact on Local and Systemic Inflammation and Myocardial Remodeling

Biomedicines

Introduction. Chronic systemic inflammation is a major driver of myocardial fibrosis in patients with metabolic syndrome; accordingly, db/db mice with impaired leptin signaling are